FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Aditxt, Inc. on the Rise After Signing Letter of Intent to Acquire a Biopharmaceutical Company”
Aditxt, Inc. (NASDAQ: ADTX) climbed 42% in premarket trading after the company signed a letter of intent to acquire a biopharmaceutical company commercializing COVID-19 antiviral oral therapy.
The biopharmaceutical company is currently selling its products under emergency and compassionate use, standard of care, and full approval in multiple countries internationally outside of the U.S. and Canada and the parties have agreed to an exclusivity period until September 30, 2021, with a view to settling the definitive agreement.
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
For more information, please visit: Aditxt, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.